极早期系统性硬化症诊断(VEDOSS)患者的皮肤和血清中存在系统性硬化的生物学标志
该研究纳入114例连续VEDOSS患者(其中36例同意皮肤活检),分析皮肤组织学、真皮成纤维细胞基因表达与收缩功能,以及血清CXCL10和ELF评分,并与健康对照及SSc样本比较。结果显示VEDOSS患者虽未满足分类标准,但皮肤和血清已出现纤维化及免疫失调的生物学活动;中位随访27.5个月时14.9%进展为SSc,基线CXCL10在进展者中显著升高且与ELF评分相关。
要点
- VEDOSS患者皮肤活检可见胶原染色和皮肤厚度增加、CD45阳性细胞血管周围浸润及CXCL10表达增加。
- VEDOSS真皮成纤维细胞促纤维化基因表达和收缩能力较健康对照增加。
- VEDOSS血清CXCL10和ELF评分与健康对照存在差异,基线CXCL10在进展为SSc者中显著升高。
核心结论
- VEDOSS患者虽未满足分类标准,但组织和血清中已显示SSc相关的纤维化和免疫失调,支持疾病的生物学诊断及在可干预的生物学通路中早期检测的机会窗口。
研究设计与样本
- 研究纳入114例连续VEDOSS患者,其中36例同意皮肤活检;皮肤活检进行组织学分析,真皮成纤维细胞采用RT-qPCR和凝胶收缩试验分析,血清采用Luminex检测CXCL10或ELISA检测ELF评分,并以健康对照和SSc生物样本作为对照。
主要发现
- 皮肤活检显示胶原染色和皮肤厚度总体增加但程度不一,CD45阳性细胞血管周围浸润及CXCL10表达增加。
- 体外实验中VEDOSS真皮成纤维细胞较健康对照显示促纤维化基因表达和收缩能力增加。
- VEDOSS血清CXCL10均值(标准差)为75.90(107.80)pg/ml,健康对照为39.90(26.27)pg/ml,P=0.02;VEDOSS的ELF评分为8.19(0.78),健康对照为8.55(0.79),P=0.04。
- 中位随访27.5个月(四分位距44.5个月)的纵向分析中,14.9%的VEDOSS患者进展为SSc。
- 进展为SSc的VEDOSS患者基线血清CXCL10浓度显著更高(增加2倍,P=0.0071),且与ELF评分相关(R=0.3096,P=0.0065)。
关键数值与推荐
- VEDOSS患者血清CXCL10均值(标准差)75.90(107.80)pg/ml vs 健康对照39.90(26.27)pg/ml,P=0.02。
- VEDOSS患者ELF评分8.19(0.78)vs 健康对照8.55(0.79),P=0.04。
- 中位随访27.5个月(四分位距44.5个月)时14.9%的VEDOSS患者进展为SSc。
- 进展为SSc的VEDOSS患者基线血清CXCL10较未进展者增加2倍,P=0.0071;基线CXCL10与ELF评分相关,R=0.3096,P=0.0065。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR study showed that, despite not showing any clinical sign of disease, patients with Raynaud's and ANA and/or capillaroscopy abnormalities often progress to SSc within 5 years. We aimed to determine whether VEDOSS biosamples show biological SSc activity pre-clinically. METHODS: Skin biopsies were histologically analysed. Dermal fibroblasts analysed by RT-qPCR and gel contraction assays. Sera were assayed by Luminex (CXCL10) or ELISA (ELF score). Healthy controls (HC) and SSc biosamples were used for controls. RESULTS: Overall, 114 consecutive VEDOSS patients were enrolled, of which 36 consented to have skin biopsies. Skin biopsies showed a variable but overall increased collagen staining and skin thickness, increased perivascular infiltrate of CD45-positive cells and CXCL10 expression. In vitro, VEDOSS dermal fibroblasts showed increased profibrotic gene expression and contractibility compared with HC. Increased serological CXCL10 [mean (s.d.) 75.90 (107.80) vs HC 39.90 (26.27) pg/ml, P = 0.02] and ELF score was evident in VEDOSS compared with HC [8.19 (0.78) vs 8.55 (0.79), P = 0.04]. In longitudinal analysis of a median of 27.5 (interquartile range 44.5) months, 14.9% of VEDOSS patients progressed to SSc. Baseline CXCL10 serum concentration was significantly higher in the VEDOSS patients that progressed (2-fold increase, P = 0.0071) and correlated with ELF score (R = 0.3096, P = 0.0065). CONCLUSIONS: Despite not fulfilling classification criteria, VEDOSS patients show SSc-linked fibrosis and immunity dysregulation both within the tissue and sera, supporting a biological diagnosis of disease and a window of opportunity to detect the biological pathways amenable for preventive intervention.
引用
- Ross RL, Caballero-Ruiz B, Clarke EL, et al. Biological hallmarks of systemic sclerosis are present in the skin and serum of patients with Very Early Diagnosis of Systemic Sclerosis (VEDOSS). Rheumatology (Oxford). 2025. PMID: 39700423. doi:10.1093/rheumatology/keae698
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。